Publish date:

Jim Cramer: AstraZeneca Is Reinventing Itself in Anti-Cancer

Jim Cramer comments on AstraZeneca's recent success in a cancer drug trial.
Author:

TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer comments on AstraZeneca's (AZN) - Get Report  recent success in a cancer drug trial. "AstraZeneca has done some great work reinventing itself with the anti-cancer franchise," Cramer says, adding that it's not a stock he has been fond of in the past amid sluggish growth. On Wednesday, the company said positive results were achieved in a trial test of its Lynparza drug, a remedy for ovarian cancer. Shares are down 12.5% since the start of the year and slipped 0.3% in midday trading Wednesday.

TST Recommends